Giv′at-Shmuel, Israel

Revital Aricha

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Brainstorm Cell Therapeutics Ltd.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Revital Aricha: Innovator in Exosome Research

Introduction

Revital Aricha is a notable inventor based in Giv'at Shmuel, Israel. She has made significant contributions to the field of biotechnology, particularly in the area of exosome research. Her work focuses on developing innovative solutions for treating neurodegenerative diseases.

Latest Patents

Revital Aricha holds a patent for "MSC-NTF specific exosomes and use thereof." This patent encompasses highly-characterized isolated exosomes, methods for their production, and their application in treating various diseases, including neurodegenerative conditions. The patent highlights her commitment to advancing medical science through innovative research.

Career Highlights

Throughout her career, Revital has demonstrated a strong dedication to scientific research and innovation. She has been instrumental in the development of new therapeutic approaches that leverage the unique properties of exosomes. Her work has the potential to transform treatment options for patients suffering from debilitating diseases.

Collaborations

Revital collaborates with esteemed colleagues, including Jonathan Semo and Yael Gothelf. These partnerships enhance her research efforts and contribute to the advancement of knowledge in the field of exosome therapy.

Conclusion

Revital Aricha is a pioneering inventor whose work in exosome research is paving the way for new treatments for neurodegenerative diseases. Her innovative spirit and dedication to science continue to inspire advancements in biotechnology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…